Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details [SPECIAL ARTICLE]

Conclusion No trial to date has demonstrated survival superiority of IAD compared with CAD. Trials concluding IAD is noninferior to CAD were based on wide NIMs that included clinically important survival differences, not likely to be considered comparable by physicians or patients. Interim analyses relying on short follow-up and including a majority of non–prostate cancer deaths will favor a noninferiority conclusion and should be interpreted cautiously. Adequate follow-up is required to ensure capture of prostate cancer deaths in both superiority and noninferiority trials.

http://jco.ascopubs.org/cgi/content/short/34/3/280?rss=1

Source: Journal of Clinical Oncology - January 12, 2016 Category: Cancer & Oncology Authors: Hussain, Tangen, Higano, Vogelzang, Thompson Tags: SPECIAL ARTICLE Source Type: research